Nanotechnology Now - Press Release: Using chitosan core-shell nanoparticle for breast cancer treatment

Home > Press > Using chitosan core-shell nanoparticle for breast cancer treatment

Abstract:
Researchers at National Nanotechnology Center (NANOTEC) and King Mongkut's University of Technology Thonburi (KMUTT) have successfully developed a target drug delivery system using folate-conjugated pluronic F127/chitosan core-shell nanoparticles to deliver doxorubicin (DOX) to target cancer cells focusing on breast cancer.

Using chitosan core-shell nanoparticle for breast cancer treatment

Pathumthani, Thailand | Posted on May 31st, 2012

"DOX is one of the most commonly used chemotherapeutic agents for cancer treatment including breast cancer. However, DOX is also considered a poor soluble drug that is toxic to healthy tissues" said Dr. Nuttaporn Pimpha, a NANOTEC researcher at Hybrid Nanostructure and Nanocomposite. "By using core-shell nanoparticles from folate-conjugated pluronic F127/chitosan we were able to develop a delivery vector that has greater targeting ability, chemical stability and lower cytotoxicity".

As in many developing countries, cancer in Thailand is becoming a significant health problem. Cervix and breast cancer is the leading cause of death in Thai women. The only commercial DOX - encapsulated liposome available is Doxil. However, Doxil has a short half-life in microcirculation and is unstable in the blood stream. Hence there is a need to find a more controlled and stable DOX carrier system.

The researchers reported their work in a paper published by the Journal of Nanomaterials.

####

For more information, please click here

Contacts:
Ramjitti Indaraprasirt
Manager
Public Relations Section
NANOTEC
02-564-7100 ext: 6617

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: